Clinical trials: Docetaxel, completed
Neoplasm Malignant
A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
Primary Objective: To confirm the dose of aflibercept in western studies by assessing the dose-limiting toxicity (DLT) of intravenous (IV) aflibercept when administered in combination with docetaxel given intravenously every 3…
- Trial name
- NCT01148615
- Testing
- Aflibercept (AVE0005), Docetaxel (XRP6976)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sanofi
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Breast Cancer
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) negative, node positive breast…
- Trial name
- NCT00129935
- Testing
- Docetaxel, Capecitabine, Epirubicin
- Where
- 58 sites in Spain
- Volunteers
- 1,384 people
- Sponsor
- Spanish Breast Cancer Research Group
Neoplasms
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology.
- Trial name
- NCT02723955
- Testing
- feladilimab (GSK3359609), GSK3174998, Pembrolizumab
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 829 people
- Sponsor
- GlaxoSmithKline
CYP3A Phenotyping, CYP3A5 and MDR1 Genotyping
Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Twenty patients with verified high risk breast cancer will be included in the study. Patients will receive three cycles of docetaxel followed by three cycles of CEF for their adjuvant treatment.
- Conditions
- CYP3A Phenotyping, CYP3A5 and MDR1 Genotyping, Docetaxel Toxicity, Associations Between Genetic Data and Docetaxel Toxicity
- Trial name
- Docetaxel (NCT01110291)
- Testing
- docetaxel + CEF
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- University of Turku
Lung Neoplasms
Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax
The purpose of this study is: to assess the efficacy of the combination in terms of Objective (clinical and radiological) Response Rate to assess the time to progression of the disease; assess the safety profile of the…
- Trial name
- NCT00826852
- Testing
- docetaxel and carboplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people
- Sponsor
- Sanofi
Head and Neck Cancer
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
- Trial name
- NCT03894891
- Testing
- Nivolumab, Cisplatin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma, Carcinoma of Head and/or Neck
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine the safety and maximum tolerated dose of the combination taxotere, cisplatin, 5-fluorouracil and leucovorin.
- Trial name
- NCT00139243
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in untreated patients…
- Trial name
- NCT00209690
- Testing
- Taxotere, 5-FU, Briplatin
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Carcinoma, Non-Small-Cell Lung
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
This Phase 1/2 clinical trial is a multi-center, open-label study with three main objectives. The first (Phase 1A) is to determine the maximum-tolerated dose of DN-101 when administered in combination with Taxotere (docetaxel)…
- Trial name
- NCT00066885
- Testing
- calcitriol + docetaxel
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novacea
Solid Tumor
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable disease.
- Trial name
- NCT00888108
- Testing
- ABT-263, Docetaxel
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 41 people
- Sponsor
- Abbott
HER2-positive Breast Cancer
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel versus placebo and trastuzumab plus docetaxel given as neoadjuvant…
- Trial name
- NCT03588091
- Testing
- Pyrotinib, Trastuzumab, Docetaxel
- Where
- 17 sites in China
- Volunteers
- 355 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer
Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine. Aim of the study is to assess the optimal dosage and safety in this setting.
- Trial name
- NCT00191243
- Testing
- Gemcitabine, docetaxel
- Where
- 8 sites in Finland
- Volunteers
- 237 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
- Trial name
- NCT00090610
- Testing
- Docetaxel, Carboplatin
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Duke University
Breast Cancer
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00872625
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Antoine Lacassagne
Pancreatic Cancer
Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, capecitabine, gemcitabine hydrochloride, epirubicin hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- PACT-9 (NCT00966706)
- Testing
- capecitabine, cisplatin, docetaxel
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080665
- Testing
- docetaxel, imatinib mesylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone-refractory Prostate Cancer
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
This is a Phase II, non-randomized, open label study of ILX651 in patients with hormone-refractory prostate cancer previously treated with docetaxel.
- Trial name
- NCT00082134
- Testing
- ILX651
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Ovarian Neoplasms
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
The purpose of this study is to assess the efficacy and the safety of the treatment.
- Trial name
- Tax-Over (NCT00772863)
- Testing
- docetaxel and cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Sanofi
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01107639
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 57 sites in Austria, France and 3 more
- Volunteers
- 297 people
- Sponsor
- Swiss Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.